Chapter 30. Non-Insulin Parenteral Therapies

  1. Richard I. G. Holt MA, MB BChir, PhD, FRCP, FHEA Professor in Diabetes & Endocrinology4,
  2. Clive S. Cockram MB BS, BSc, MD (Lond), FRCP, FRACP, FHKAM (Med) Emeritus Professor of Medicine5,
  3. Allan Flyvbjerg MD, DMSc Professor of Clinical Endocrinology Chair6 and
  4. Barry J. Goldstein MD, PhD, FACP, FACE Therapeutic Area Head Vice President7
  1. Jens Juul Holst MD, DMSc Professor1,
  2. Sten Madsbad MD, DMSc Professor2 and
  3. Ole Schmitz MD, DMSc Professor3

Published Online: 9 JUL 2010

DOI: 10.1002/9781444324808.ch30

Textbook of Diabetes, Fourth Edition

Textbook of Diabetes, Fourth Edition

How to Cite

Holst, J. J., Madsbad, S. and Schmitz, O. (2010) Non-Insulin Parenteral Therapies, in Textbook of Diabetes, Fourth Edition (eds R. I. G. Holt, C. S. Cockram, A. Flyvbjerg and B. J. Goldstein), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444324808.ch30

Editor Information

  1. 4

    Developmental Origins of Health and Disease Division, University of Southampton School of Medicine, Southampton, UK

  2. 5

    Chinese University of Hong Kong, Hong Kong SAR, People's Republic of China

  3. 6

    Department of Endocrinology and Internal Medicine, The Medical Research Laboratories, Aarhus University Hospital – Aarhus University, Aarhus, Denmark

  4. 7

    Clinical Research, Metabolism Merck Research Laboratories Rahway, NJ, USA

Author Information

  1. 1

    Department of Biomedical Sciences, The Panum Institute, University of Copenhagen, Denmark

  2. 2

    Department of Endocrinology, Hvidovre Hospital, Hvidovre, Denmark

  3. 3

    Department of Clinical Pharmacology, Aarhus University Hospital, Denmark

Publication History

  1. Published Online: 9 JUL 2010
  2. Published Print: 9 JUL 2010

ISBN Information

Print ISBN: 9781405191814

Online ISBN: 9781444324808

SEARCH

Keywords:

  • GLP-1 receptor activators;
  • GLP-1 receptor agonists;
  • Comparison of GLP - 1 receptor agonists with DPP - 4 inhibitors;
  • Comments on GLP - 1 receptor agonists;
  • Amylin and amylin analogs;
  • Effects of the amylin analog pramlintide in human studies;
  • Side effects and drawbacks of pramlintide treatment

Summary

This chapter contains sections titled:

  • GLP-1 receptor activators

  • GLP-1 receptor agonists

  • Amylin and amylin analogs

  • References